Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Centoxin

J Davidson1, M Tarlow

  • 1Department of Paediatrics, University of Birmingham.

British Journal of Hospital Medicine
|January 2, 1993
PubMed
Summary
This summary is machine-generated.

Centoxin, a novel immunotherapeutic agent, offers a new treatment approach for Gram-negative septicaemia. This therapy utilizes humanized antibodies derived from monoclonal antibody technology for patient management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for the Collective Nature of Radial Flow in Pb+Pb Collisions with the ATLAS Detector.

Physical review letters·2026
Same author

Evidence for the Dimuon Decay of the Higgs Boson in pp Collisions with the ATLAS Detector.

Physical review letters·2025
Same author

Evidence for Longitudinally Polarized W Bosons in the Electroweak Production of Same-Sign W Boson Pairs in Association with Two Jets in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Global Burden of Animal Diseases informatics strategy, data quality and model interoperability.

Revue scientifique et technique (International Office of Epizootics)·2024
Same author

Evaluating the efficacy and safety of neonatal chyme reinfusion therapy: A feasibility study using a novel medical device.

Clinical nutrition (Edinburgh, Scotland)·2024
Same author

To Prevent the Spreading of Scarlet Fever.

The Bistoury·2023
Same journal

The autopsy in the 1990s.

British journal of hospital medicine·1999
Same journal

Screening for breast cancer.

British journal of hospital medicine·1999
Same journal

Cost-effective monotherapy of concomitant benign prostatic hyperplasia and hypertension.

British journal of hospital medicine·1999
Same journal

Liposarcoma: a review of current diagnosis and management.

British journal of hospital medicine·1999
Same journal

How to do it in surgery: laparoscopic rectopexy.

British journal of hospital medicine·1999
Same journal

The management of ovarian cancer.

British journal of hospital medicine·1999
See all related articles

Area of Science:

  • Immunotherapy
  • Monoclonal Antibody Technology
  • Septicemia Management

Background:

  • Gram-negative septicaemia poses a significant clinical challenge.
  • Existing treatment modalities have limitations.
  • Novel therapeutic strategies are needed.

Purpose of the Study:

  • To introduce Centoxin as a new immunotherapeutic agent.
  • To highlight its indication in managing Gram-negative septicaemia.
  • To present a novel treatment approach.

Main Methods:

  • Centoxin is manufactured using monoclonal antibody technology.
  • The agent is derived from 'humanized' antibodies.
  • Clinical application in patients with Gram-negative septicaemia.

Related Experiment Videos

Main Results:

  • Centoxin represents a new approach to treating Gram-negative septicaemia.
  • Its introduction offers a potential advancement in patient management.
  • Clinical efficacy data is pending further investigation.

Conclusions:

  • Centoxin is a promising immunotherapeutic agent for Gram-negative septicaemia.
  • The use of humanized monoclonal antibodies marks a new therapeutic avenue.
  • Further research is warranted to establish its full clinical impact.